Clinical Trials Browser

Interventional × Has results × trilaciclib × Clear all

NCT02514447 2025-09-25

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Phase 1/2 Completed

123 enrolled 46 charts

Small Cell Lung Carcinoma

NCT03041311 2025-09-25

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Phase 2 Completed

107 enrolled 42 charts

Small Cell Lung Carcinoma

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT04902885 2024-07-10

Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients

Phase 3 Completed

95 enrolled 27 charts

Small Cell Lung Carcinoma

NCT04863248 2023-04-14

PRESERVE 4

Phase 2 Terminated

10 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02978716 2022-03-23

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Phase 2 Terminated

102 enrolled 51 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02499770 2020-08-21

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Phase 1/2 Completed

122 enrolled 62 charts

Small Cell Lung Carcinoma